Skip to main content

Upcoming holiday closures 

Quest Patient Service Centers will be closed on Friday, July 3 and Saturday, July 4, 2026, in observance of Independence Day, and to give our frontline team the time to recharge. Don't let the holiday interrupt your care. Plan your visit today.

Hide
Quest Diagnostics

Assessment of Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations in Patients in Prescription Drug Monitoring Programs

SOFT 2020: Society of Forensic Toxicologists 
Virtual [in-person conference canceled], September 21-25, 2020

Assessment of urinary buprenorphine, norbuprenorphine and naloxone concentrations in patients in prescription drug monitoring programs

Authors: Solano R, Jenkins AJ

Specialties: Prescription drug monitoring, Toxicology

Related content

Audio Podcast
Dangerous Drug Combinations
Test FAQ
Drug Toxicology Monitoring Oral Fluid Testing
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Test FAQ
Novel Psychoactive Substances (NPS) Panel
Audio Podcast
Presumptive vs Definitive Drug Testing: What You Need to Know

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.